Competitive Technologies Signs Agreement For Distribution In India Of Pain Management Device

Fairfield, CT - Competitive Technologies, Inc. announced recently that it has signed an agreement with Excel Life Sciences, Inc. (ELS) granting them exclusive distribution rights in India for CTT's pain management therapy device. The device is a non-invasive method for rapid treatment of high-intensity oncologic and neuropathic pain, including pain resistant to morphine and other drugs. The European Union's Medical Device CE certification allows the device to be registered for sales in India.

ELS is a U.S.-based, India-focused provider of clinical research and healthcare services. They also have a special focus on improving patient care in the markets in which they operate. ELS has a fully owned Indian subsidiary with its main office in New Delhi, with 16 operational locations serving a network of over 700 hospitals across India.

"ELS will be a strong, strategic partner for CTT in the important Indian market," said Aris D. Despo, CTT's Executive VP, Business Development. "India's $1.75B medical device market, supported by its growing middle and upper classes of over 150 million people, represents a significant opportunity for sales of our innovative pain management technology."

"Over 4 million people in India suffer from severe cancer, neuropathic pain and other forms of chronic disabling pain. We expect this pain management device to usher in a paradigm shift in perception and treatment of pain. This device will go a long way in reducing dependence on narcotic analgesics, and improving quality of life for millions of patients," said Dr. Vijay Kumar, ELS' President and Chief Medical Officer.

Developed in Italy by CTT's client, Prof. Giuseppe Marineo, the device was brought to CTT through the efforts of Prof. Giancarlo Elia Valori of the Italian business development group, Sviluppo Lazio S.p.A., and assistance from the Zangani Investor Community. The device, with a biophysical rather than a biochemical approach, uses a multi-processor able to simultaneously treat multiple pain areas by applying surface electrodes to the skin. CTT has exclusive worldwide rights to the therapy device. CTT partner GEOMC Co., Ltd. of Korea, is producing the device commercially for worldwide distribution.

Mohit Mehrotra, ELS's Founder and Chief Operating Officer, commented, "We are proud to work with CTT to bring this important device and progressive medical technology to India. Our extensive knowledge about healthcare in India, along with a large network of research hospitals and clinics, helps us understand the expectations and needs of both patients and healthcare providers. This device will revolutionize pain management for both constituents."

The device has been used on over 2,300 patients in seven hospitals in Europe, including the Pain Management Center at Tor-Vergata University Medical Center in Rome (http://www.ptvonline.it/uo_ter_ant_ing.asp).

CTT has filed for FDA 510(k) medical device authorization for U.S. sales, as well as seeking approval for sales in other countries. CTT is currently in the process of selecting distributors from a targeted list of companies representing the U.S. and global markets in Europe, Asia and Latin America. Revenue is expected to grow in succeeding years as global market penetration increases. CTT expects revenues to be approximately $20M per year, as the device attains mature market levels.

"We believe that revenue and profits from the pain management technology will dramatically exceed those produced by any other technology in our 40-year history," said John B. Nano, CTT's Chairman, President and CEO. "There is exciting potential for its success in the global pain management market; a market estimated to reach $40 billion by 2010."

Mr. Nano continued, "This is another example of a CTT technology being at the forefront of the paradigm shift to treat individuals with integrative medicine, combining traditional and holistic medicine. CTT's management team is focused on creating value from technologies, restoring stockholder value by signing new license agreements. In addition to the pain management therapy, we are aggressively marketing the breast cancer detection test, MC Square stress reduction device (http://www.relaxmc.com), UAD surgical prosthetics, and solar technologies to drive revenue growth, improve profitability and create shareholder value. Our full technology portfolio may be viewed on our website."

SOURCE: Competitive Technologies, Inc.